 One recommendation that we do point to in our report involves the pending BioSecure Act, which has bipartisan support but hasn't yet passed out of the House or Senate. That would begin a narrow decoupling of U.S. government contractor pharmaceutical and biotech companies from certain identified Chinese providers of biopharmaceutical services.